ProVise Management Group LLC Purchases 733 Shares of Sanofi (NASDAQ:SNY)

ProVise Management Group LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 0.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 187,427 shares of the company’s stock after purchasing an additional 733 shares during the quarter. ProVise Management Group LLC’s holdings in Sanofi were worth $9,040,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Boston Partners boosted its holdings in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares during the last quarter. Natixis Advisors LLC boosted its holdings in shares of Sanofi by 1.2% during the 4th quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock valued at $140,350,000 after acquiring an additional 35,828 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Sanofi during the 4th quarter valued at about $135,933,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $59.11 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1-year low of $45.22 and a 1-year high of $60.12. The company has a market capitalization of $150.01 billion, a P/E ratio of 23.74, a P/E/G ratio of 1.01 and a beta of 0.58. The firm’s 50 day simple moving average is $54.03 and its two-hundred day simple moving average is $52.85.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and an average price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.